Thursday, October 25, 2018

07:00-10:30

ITMIG Committee meetings open to all conference participants

• • 07:00 – 07:30: Education Committee Meeting
• • 07:30 – 08:30: Steering Committee Meeting
• • 08:30 – 09:30: Biology/Pathology Committee Meeting
• • 09:30 – 10:00: Database Committee Meeting

10:00-12:00

Local Hospital Visit, Asan Medical Center

17:30

Opening Reception

Friday, October 26, 2018

08:00-09:00

KSCTS Abstract Session in English

09:00-10:00

ITMIG I – KART Presentations

• • 09:00 – 09:20: Impact of lymph node dissection on thymic malignancy:
  The Korean Association for Research on the Thymus (KART) Database Study –Yoohwa Hwang
• • 09:20 – 09:40: Minimally invasive surgery of thymic tumors – Geun Dong Lee
• • 09:40 – 10:00: Technical advances of radiotherapy for thymic epithelial tumors
  – Jae Myoung Noh

10:00-10:30

Coffee Break

10:30-12:30

ITMIG II – Imaging

• • 10:30 – 11:00: ITMIG Projects – ITMIG Database and Other Updates
• • 11:00 – 11:20: Approach to Prevascular Mass – Nori Tomiyama
• • 11:20 – 11:35: Clinical TNM Staging of Thymic Epithelial Malignancies – Jeanne Ackman
• • 11:35 – 12:00: Determining extent of invasion and follow-up of thymic epithelial malignancies – Marcelo Benven
• • 12:00 – 12:20: Management of the incidentally detected prevascular mass
  – Soon Ho Yoon
• • 12:20 – 12:30: Imaging panel questions and answers – EM Maron, Nori Tomiyama, Jeanne Ackman, Marcelo Benveniste, Soon Ho Yoon

12:30-13:30

Luncheon

13:30-15:00

ITMIG III – Abstracts

• • 13:30 – 13:40: Tumor Size as a Prognostic Factor in Limited Stage Thymic Epithelial Tumors: A Multicenter Analysis – Jae Kwang Yun
• • 13:40 – 13:50: Modified Subxiphoid Thoracoscopic versus Unilateral Thoracoscopic Approach for Early-stage Thymomas without MG – Jianyong Ding
• • 13:50 – 14:00: Compare two assessment criteria for thymic epithelial tumors after chemoradiotherapy – Xingwen Fan
• • 14:00 – 14:10: Predictors of Occult Pleural Dissemination Detected Intraoperatively in Patients with Thymic Tumors – Weigang Zhao
• • Prognostic factor of T3N0M0 thymic epithelial tumor with complete resection
  – Yi-Ting Yen
• • 14:10 – 14:20: Incidence and Pathological Features of Thymomathous Myasthenia Gravis after Thymectomy at a Tertiary-level Center – Arthur Vieira
• • 14:20 – 14:30: CD70 in thymic carcinoma: a promising diagnostic marker
  – Jumpei Kashima
• • 14:30 – 14:40: Thymic carcinoma: preliminary data of Next Generation Sequencing (NGS) analysis – Mirella Marino
• • 14:40 – 14:50: Gene expression profile reveals new biomarker for novel diagnosis and therapy in thymic and pulmonary carcinomas. – Djeda Belharazem

15:30 – 17:30

Clinical decision making for minimally invasive approach

• • 15:30 – 15:45: Potential red flags for VATS and for RATS thymectomy – Alper Toker
• • 15:45 – 16:00: Panel discussion and summary – V Fang, Josh Sonett, Alper Toker,
  Marcin Zielinski

 

Developing a MIS program for invasive tumors

• • 16:00 – 16:10: Is there a threshold for getting over the learning curve for MIS for TET? – Josh Sonett
• • 16:10 – 16:20: Initiating a MIS TET program: case selection, simulation, proctorship – Franca Melfi
• • 16:20 – 16:30: Using CUSUM monitoring of a new program – Nuria Novoa
• • 16:30 – 16:45: Panel discussion on training – Josh Sonett, Franca Melfi, Nuria Novona,
  A Kirk, Young Soo Choi

 

Node dissection in an Era of Minimally Invasive Resection: Is it important?

• • 16:45 – 16:55: What extent of node sampling or dissection is appropriate? – In Kyu Park
• • 16:55 – 17:05: Difficulties in node assessment with MIS and potential solutions – Takashi Suda
• • 17:05 – 17:15 – Extent of node assessment and 9th edition refinement of TNM stage classification – Enrico Ruffini
• • 17:15 – 17:30: Panel discussion – In Kyu Park, Takashi Suda, Enrico Ruffini,
  Chang Yung Lee, Y Hwang, Meinoshin Okumura

Saturday, October 27, 2018

08:00-09:00

KSCTS Abstract session in English

09:00-10:00

ITMIG V – Pleural

• • 09:00 – 09:15: Chemotherapy for stage IVA thymic tumors: neoadjuvant or adjuvant, intrapleural or systemic? – Nicolas Girard
• • 09:15 – 09:30: Surgery and intrapleural therapy for stage IVA thymic tumors
  – S Cho
• • 09:30 – 09:45: Radiotherapy for stage IVA thymic tumors – Changlu Wang
• • 09:45 – 10:00: Panel Discussion – Nicolas Girard, S Cho, Changlu Wang, Vincent Fang

10:30-12:00

ITMIG VI – Medical Oncology/Basic Science

• • 10:30 – 10:50: Deciphering the biology of thymic tumors – Arun Rajan
• • 10:50 – 11:10: Next Generation Sequencing: is it useful for routine practice?
  – Nicholas Girard
• • 11:10 – 11:30: Systemic treatment of TET: Lessons from clinical trials – Keunchil Park
• • 11:30 – 11:50: Immune checkpoint inhibitors: how to move forward? – Arun Rajan
• • 11:50 – 12:00: Panel discussion – Nicolas Girard, Keunchil Park, Arun Rajan

13:00-14:00

ITMIG VII – Abstracts

• • 13:00 – 13:10: Comparison of factors affecting length of stay after surgery for thymic tumors: minimally invasive vs open surgeries – Kwon Joong Na
• • 13:10 – 13:20: The Importance of Measuring Acetylcholine Receptor Antibodies in Thymomas – Florit Marcuse
• • 13:20 – 13:30: Adjuvant chemotherapy improved survival of completely resected squamous thymic carcinoma – Wang Changlu
• • 13:30 – 13:40: MRI for the Follow-up of Treated Thymic Epithelial Malignancies
  – Ariel Kerpel
• • 13:40 – 13:50: The Role of Postoperative Radiotherapy in Stage II and III Thymoma: A Korean Multicenter Database Study – Seung Hwan Song
• • 13:50 – 14:00: A dosimetric comparison of VMAT and IMPT with and without aperture for thymic cancer – Kwanghyun Jo

14:00-17:00

ITMIG VII – Tumor Board

Poster Presentations

• • P-001 – Evaluation of the New TNM Staging System in 189 Patients with Thymic Carcinomas: Impact on Indication and Survival, Yu Yang, Fudan University Shanghai Cancer Center, China
• • P-002 – Thymoma in late-onset myasthenia gravis several years after initial normal chest imaging: two illustrative cases, Pedro Rodriguez Cruz, University of Oxford, UK
• • P-003 – Thymoma in early-onset myasthenia gravis following prior thymectomy with normal histology, Pedro Rodriguez Cruz, Oxford University, UK
• • P-004 – Cetuximab in pre-treated thymic epithelial tumors: a monocentric real life experience in selected population, Margaret Ottaviano, Rare Tumours Reference Center, University Federico II of Naples, Italy
• • P-005 – IL-8 can be used for the differential diagnosis of thymic epithelial tumors, Jianyong Ding, Zhongshan Hospital, China
• • P-006 – EGFR signature in B thymoma, Giovannella Palmieri, Rare Tumours Reference Center, University Federico II of Naples, Italy
• • P-007 – KIT mutation and expression in thymic carcinomas – clinicopathological and molecular analysis, Malgorzata Szolkowska, National Tuberculosis and Lung Diseases Research Institute, Poland
• • P-008 – Occurrence of a coexpression of the thymic markers CD5 and CD117 in a series of 251 lung squamous cell carcinomas ., Thierry Molina, Hôpital Necker, AP-HP, Paris descartes University, France
• • P-009 – Different pattern of PD-L1, STAT1 and STAT3 expression with survival in thymoma and thymic carcinoma, Yi-Ting Yen, National Cheng Kung University Hospital, Taiwan
• • P-010 – Abnormal wnt signaling in thymic epithelial tumors inhibits senescence and aging gene signatures, Xiaonan Zhang, Medical Faculty Mannheim, University of Heidelberg, Germany
• • P-011 – Thymoma treatment our experience., Fadil Gradica, University Hospital “Shefqet Ndroqi”, Albania
• • P-012 – Role of neutrophil-to-lymphocyte ratio on prognosis of early-stage, radically resected thymomas, Gianluca Perroni, Tor Vergata University, Italy
• • P-013 – Robotic thymectomy – does it really shorten the learning curve in minimally invasive thymectomy?, George Karimundackal, Tata Memorial Hospital, India
• • P-014 – The Role of Robotic Assisted Thoracoscopic Surgery in the Treatment of Large Malignant Thymic Tumours, Henrietta Wilson, Barts Health NHS Trust, UK
• • P-015 – Multidisciplinary management of recurrence after thymoma radical resection: an Italian experience, Enrico Ruffini, University of Torino, Italy
• • P-016 – Reconstruction of the superior vena cava in patients with thymic malignancies, Lei Yu, Beijing Tongren Hospital, Capital Medical University, China
• • P-017 – Minimal invasive thymectomy is feasible for the surgical treatment of large size thymic tumors, NING Xu, Shanghai Chest Hospital, China
• • P-018 – Is minimally invasive thymectomy an acceptable approach for locally advanced thymic malignances?, Zhitao Gu, Shanghai Chest Hospital, China
• • P-019 – Exploratory Study of Guiding Significance for The Technology of CD-DST in The Chemotherapy of Thymoma, Lei Yu, Beijing Tongren Hospital, Capital Medical University, China
• • P-020 – Long term outcomes in patients undergoing surgical resection of thymoma: a single institution experience, Hannah Ng, Tan Tock Seng Hospital, Singapore
• • P-021 – The significance of the Prognostic Nutrition Index in patients with thymic carcinoma or thymic neuroendocrine tumor, Masahiro Yanagiya, The University of Tokyo Graduate School of Medicine, Japan